ACC CardiaCast: Which Patients Can Benefit from the Newly-Approved Cardiac Myosin Inhibitor Recently Approved for HCM

In this episode, Drs. Matt Martinez and Sara Saberi discuss the recent approval by the FDA of the cardiac myosin inhibitor Mavacamten for the treatment of hypertrophic cardiomyopathy, and what sorts of patients are best suited for this treatment.

Educational grant support provided by: Bristol Myers Squibb

To visit the course page for the HCM: Accelerating Guideline-Driven Care project, click here!

Clinical Topics: Heart Failure and Cardiomyopathies

Keywords: Cardiomyopathy, Hypertrophic, CardiaCast

< Back to Listings